CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
17 Apr 2024: Bristol Myers Squibb finalizes a Global Strategic License and Collaboration Agreement with SystImmune for BL-B01D1, bolstering its position in the ADC arena
- Bristol Myers Squibb has completed an exclusive license and collaboration agreement with SystImmune for BL-B01D1, a novel EGFRxHER3 bispecific antibody-drug conjugate (ADC)
- The agreement entails co-development and co-commercialization of BL-B01D1 in the United States, with SystImmune retaining exclusive rights in China and Bristol Myers Squibb securing exclusivity elsewhere
- BL-B01D1 exhibits potential in treating various cancers like lung and breast cancer, with opportunities for combination therapies with standard treatments and Bristol Myers Squibb’s pipeline assets
- BL-B01D1, developed by SystImmune, targets EGFR and HER3, common in epithelial tumors, and features a proprietary bispecific antibody and linker-payload with a stable, cleavable linker and topoisomerase inhibitor
